Alamar Biosciences CEO files initial ownership
Alamar Biosciences, Inc. Chief Executive Officer Luo Yuling filed an initial statement of beneficial ownership, listing existing share and option positions as of April 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Alamar Biosciences, Inc. Chief Executive Officer Luo Yuling filed an initial statement of beneficial ownership, listing existing share and option positions as of April 16, 2026. The filing shows direct and indirect holdings of Class A and Class B Common Stock, preferred stock, and multiple vested and time-vesting stock options.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Luo Yuling
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Founders Preferred Stock | -- | -- | -- |
| holding | Series A-1 Preferred Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 1,020,742 contracts (Direct);
Class A Common Stock — 1,224,152 contracts (Indirect, By Spouse);
Founders Preferred Stock — 366,004 contracts (Direct);
Series A-1 Preferred Stock — 364,268 contracts (Direct);
Stock Option (Right to Buy) — 1,476,662 contracts (Direct);
Class B Common Stock — 113,051 shares (Direct)
Footnotes (8)
- F1. Each share of Class A Common Stock and Founders Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-1 basis, at the holder's election, and will automatically convert into shares of Class B Common Stock immediately prior to the closing of the Issuer's initial public offering. The Class A Common Stock has no expiration date.
- F2. The preferred stock is convertible into shares of Class B Common Stock on a 1-for-2.418 basis, at the holder's election, and will automatically convert into shares of the Issuer's common stock upon the closing of the initial public offering pursuant to their terms. The preferred stock has no expiration date.
- F3. Fully vested.
- F4. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date.
- F5. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.
- F6. The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
- F7. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
- F8. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Key Figures
Direct Class B Common Stock: 113,051 shares
Direct Class A Common Stock: 1,020,742 shares
Indirect Class A Common Stock: 1,224,152 shares
+5 more
8 metrics
Direct Class B Common Stock
113,051 shares
Direct Class B Common Stock held as of April 16, 2026
Direct Class A Common Stock
1,020,742 shares
Direct Class A Common Stock held as of April 16, 2026
Indirect Class A Common Stock
1,224,152 shares
Class A Common Stock held indirectly by spouse as of April 16, 2026
Option at $7.6000
42,334 underlying shares
Stock Option on Class B Common Stock, exercise price $7.6000, expiring January 14, 2036
Large option at $3.3400
1,033,912 underlying shares
Stock Option on Class B Common Stock, exercise price $3.3400, expiring January 15, 2035
Series A-1 Preferred Stock
364,268 underlying shares
Series A-1 Preferred convertible into Class B Common Stock on 1-for-2.418 basis
Founders Preferred Stock
366,004 underlying shares
Founders Preferred Stock convertible into Class B Common Stock on 1-for-1 basis
Vesting schedule length
48 months
Options vest in equal monthly installments over 48 months from specified start dates
Key Terms
Class B Common Stock, Stock Option (Right to Buy), Founders Preferred Stock, Series A-1 Preferred Stock, +2 more
6 terms
Class B Common Stock financial
"Each share of Class A Common Stock and Founders Preferred Stock is convertible into shares of Class B Common Stock"
A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... underlying security title Class B Common Stock"
Founders Preferred Stock financial
"Founders Preferred Stock is convertible into shares of Class B Common Stock on a 1-for-1 basis"
Series A-1 Preferred Stock financial
"The preferred stock is convertible into shares of Class B Common Stock on a 1-for-2.418 basis"
Series A-1 preferred stock is a specific class of company shares created in an early financing round that typically gives its holders priority over common shareholders for dividends and money if the company is sold or liquidates. Think of it as a special ticket with upfront privileges — often convertible into ordinary shares and sometimes carrying voting or protective rights — so investors use it to reduce risk and preserve control compared with ordinary stock.
initial public offering financial
"will automatically convert into shares of Class B Common Stock immediately prior to the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
vest in equal monthly installments financial
"The shares subject to the option vest in equal monthly installments over 48 months"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Alamar Biosciences (ALMR) CEO Luo Yuling disclose in this Form 3?
The Form 3 shows Luo Yuling’s existing ownership in Alamar Biosciences, including Class A and Class B Common Stock, Series A-1 Preferred Stock, Founders Preferred Stock, and several stock option grants, rather than reporting any new share purchases or sales.
What Class A Common Stock holdings are reported for Alamar Biosciences (ALMR)?
The Form 3 lists 1,020,742 shares of Class A Common Stock held directly and 1,224,152 shares held indirectly by the CEO’s spouse. Both classes are disclosed as convertible into Class B Common Stock under the terms described in the footnotes.
What stock options does the Alamar Biosciences CEO hold according to this Form 3?
The filing lists several stock options on Class B Common Stock, including grants with exercise prices of $7.6000, $3.3400, $2.5100, and $1.5300. These options expire between 2027 and 2036, with various underlying share amounts.
Do the Alamar Biosciences (ALMR) CEO’s options in this filing appear vested or time-based?
Some options are noted as fully vested, while others vest in equal monthly installments over 48 months from dates in 2023, 2024, 2025, or 2026, subject to the CEO’s continuous service on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates